Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Sanofi To Sell Its Doliprane Production Subsidiary

Sanofi's Doliprane medecine boxes pictured in Camps-la-source, France on September 24, 2024. While Servier gave up on selling Biogaran at the beginning of September, the project to sell Opella, Sanofi’s healthcare subsidiary, which notably houses the iconic little yellow box, is still underway. Following the first indicative offers submitted in July, the takeover candidates had until 23 September to submit their firm takeover bids. Photo by Laurent Coust/ABACAPRESS.COM

E

Illustration - Biogaran

A box of prednisolone, generic medecine of Solupred, from Biogaran laboratories in Marseille, France on April 9, 2024. Photo by Laurent Coust/ABACAPRESS.COM

E

Illustration - Biogaran

A box of prednisolone, generic medecine of Solupred, from Biogaran laboratories in Marseille, France on April 9, 2024. Photo by Laurent Coust/ABACAPRESS.COM

E